OIE Reference Laboratory annual reports (RINDERPEST)

Activities in 2021

Name (including Title) of Head of Laboratory (Responsible Official):	Prof. Bryan Charleston, Institute Director
Name (including Title and Position) of OIE Reference Expert:	Dr Michael D. Baron, Honorary Institute Fellow
Email address:	michael.baron@pirbright.ac.uk
Address of laboratory:	The Pirbright Institute, Ash Road, Pirbright, Surrey GU24 0NF
Website:	www.pirbright.ac.uk
Telephone:	+44 (0)1483 232441
Fax:	

A: Maintaining Scientific and Technical Skills

1. Did your laboratory perform relevant diagnostic tests for purposes such as disease, diagnosis, screening of animals for export, surveillance, etc. (not for quality control, proficiency testing or staff training)

    a. For the specified disease? **No**
    b. For closely related diseases or pathogens? **Yes, PPR (see separate report on PPR-related activities)**

Disease	Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of tests performed last year	
			Nationally	Internationally

2. Did your laboratory produce, supply, or import standard reference reagents officially recognised by the OIE for the specified disease or for closely related diseases? Yes, PPR (see separate report on PPR-related activities)

Type of Reagent Available	Related diagnostic test	Produced/Supplied/Imported	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	Name of recipient OIE member countries

3. Did your laboratory supply, exchange or receive standard reference reagents and/or other diagnostic reagents for the specified disease **No**

Type of reagent	Related diagnostic test	Supplied by your lab, exchanged or received	Amount	Name of recipient or supplier member country

4. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country for the specified disease or for closely related diseases? **For Rinderpest, No. For PPR, see PPR-specific report**

Name of the OIE member country receiving the technical consultancy	Purpose	How the advice was provided

5. What method of dissemination of information is most often used by your laboratory? (please provide information on activities for other diseases relevant to maintaining capability for specified disease) [a: Articles published in peer-reviewed journals; b: International conferences; c: National conferences; d: Other]

I**nformation Provided here for RPV: for PPR, see PPR-specific report**

(a) Publications in peer-reviewed journals: none on rinderpest

(b) International Conferences: none involving rinderpest

(c) National conferences: none this year

(d) Other: none

6. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

☐ Yes ☒ No

7. Did your laboratory implement activities to ensure ongoing capability for the designated disease or closely related disease in the event of loss of the key staff including the OIE Reference Expert?

Activity	Description
Laboratory enquiries, QA, diagnostics	Dr Carrie Batten continues to manage lab activities related to RPV and acts as secretariat for the RHF network.

B: Laboratory Systems

8. Does your laboratory have a Quality Management System certified according to an International Standard? If YES indicate the name of the quality management system adopted or currently in place. Also attach a scanned certificate of the system.

UKAS accreditation to ISO/IEC 17025

9. Is your laboratory accredited by an international accreditation body? If 'yes' indicate test for which your laboratory is accredited and name of the accreditation body.

Real-time RT-PCR for rinderpest virus – UKAS ISO/IEC 17025

10. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

☒ Yes ☐ No

11. Does your laboratory have a biosecurity system in place to ensure security for the pathogen and materials that may contain the infectious pathogen?

☒ Yes ☐ No

C: Capability to Respond to a Suspected Case

12. In the last year, did your laboratory perform diagnostic tests for the specified pathogen and the disease in order to confirm ongoing capability?

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of tests performed last year
Real-time RT-PCR	Yes	0

13. Did your laboratory produce vaccines for the specified disease or similar diseases? **NO**

Disease	Amount supplied nationally or internationally

14. Did your laboratory organise or participate in inter-laboratory proficiency tests with any other laboratories for the specified disease or similar diseases?

Role of your laboratory (organiser or participant)	Disease	Test	Number of participating laboratories	Regions of participating OIE member countries
Participant	PPRV	ELISA and PCR		Global

D: Networks and Linkages

15. Did your laboratory organise or participate in scientific meetings for the specified disease? **NO RELEVANT MEETINGS THIS YEAR**

Title of event	Date	Location	Role (Organiser, speaker, presenter)	Title of work presented

16. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

☒ Yes ☐ No

17. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease?

☒ Yes ☐ No

18. Did your laboratory place expert consultants at the disposal of the OIE?

☒ Yes ☐ No

19. Did your laboratory carry out activities to raise awareness and improve capability for this disease in other member countries? **NO**

Description of activity	Date	Member countries

E: Biosafety

20. What level of biocontainment is used in your laboratory for (a) storage and (b) handling of potentially infectious material for the specified disease?

All materials are stored, and potentially infectious material would be handled, at UK SAPO4, approximately equivalent to BSL3+ or BSL3-Ag.

21. Does your laboratory maintain a structured risk assessment for work with potentially infectious material for the specified disease?

☒ Yes ☐ No

22. Was your laboratory's risk assessment for work with potentially infectious material reviewed in the past year?

☒ Yes ☐ No

23. Does your laboratory have an emergency response plan for biosafety incidents involving potentially infectious material for the specified disease?

☒ Yes ☐ No

F: Research

24. Did your laboratory develop new diagnostic methods for the designated pathogen or disease, or a similar disease? **For rinderpest, NO. For PPR, see PPR-specific report**

Disease	Diagnostic Method	Description

25. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than your own? **For rinderpest, NO. For PPR, see PPR-specific report**

Title of study	Duration	Purpose of study	Partners (Institutions)	OIE Member Countries Involved other than your Country

26. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest or a similar pathogen? **For rinderpest, see below. For PPR, see PPR-specific report**

Title of Project or Contract	Scope	Name(s) of relevant OIE Reference Laboratories
Full genome sequencing of archived RPV isolates	Joint analysis of genome sequences	RPV Reference Laboratory, CIRAD, France

27. Additional comments regarding your report (if any):

Pirbright is also an RHF.
Dr Carrie Batten acts as the secretariat for the RHF network and organises 5 monthly catch up meetings, in 2021 these were virtual and occurred in May and December.